Peer-Reviewed Journal Details
Mandatory Fields
Barry, A,O'Halloran, KD,McKenna, JP,McCreary, C,Harhen, B,Kerr, DM,Finn, DP,Downer, EJ
Journal Of Oral Pathology & Medicine
Plasma N-acylethanolamine and endocannabinoid levels in burning mouth syndrome: Potential role in disease pathogenesis
Altmetric: 4WOS: 2 ()
Optional Fields
burning mouth syndrome depression endocannabinoids N-acylethanolamines neuropathic orofacial pain PALMITOYLETHANOLAMIDE BEHAVIOR PAIN
ObjectiveThe objective was to measure endocannabinoid (eCB) ligands and non-cannabinoid N-acylethanolamine (NAE) molecules in plasma from individuals with burning mouth syndrome (BMS) and to determine whether plasma eCB/NAE levels correlated with pain, inflammation and depressive symptomatology in this cohort.Study DesignPlasma content of the eCBs, anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG), and the NAE molecules, palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) were assessed in healthy subjects (n = 8) and in a cohort of newly diagnosed BMS patients (n = 9) using liquid chromatography-tandem mass spectrometry. Plasma eCBs and NAE profiles were correlated with self-rated oral cavity pain intensities, depressive symptomatology and plasma IL-8 levels.ResultsPlasma levels of PEA, but not OEA, AEA or 2-AG, were significantly elevated in patients with BMS, when compared to plasma from healthy individuals. Plasma PEA, OEA and AEA levels correlated with depressive symptomatology.ConclusionsThis is the first evidence to indicate that circulating eCB/NAE levels are altered in BMS.
Grant Details
Publication Themes